Anticoagulant Reversal Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026

Anticoagulant Reversal Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026

Anticoagulant Reversal Drugs Market - Scope of the Study

The study on the anticoagulant reversal drugs market is an exclusive report published by Fact.MR, which provides information regarding the key growth influencers of the landscape. This study offers insights on the growth of the anticoagulant reversal drugs market, by analysing the historical data for the period of 2016 - 2019, and 2020 - 2026 as the forecast period. Estimation of the revenue of the anticoagulant reversal drugs market has been carried out in terms of value (US$ Mn). This exclusive report focuses on offering information on the key trends that are likely to influence the growth of the anticoagulant reversal drugs market, in addition to crucial microscopic and macroeconomic growth indicators. The incisive report offers the key dynamics, along with their influence on the value chain, which is projected to positively impact the future growth of the anticoagulant reversal drugs market.

The study also includes a detailed section dedicated to impeders that could challenge the growth of players in the anticoagulant reversal drugs market. The report unfolds profitable opportunities for market players, which can be leveraged to consolidate their position in the global market. With a view of aiding stakeholders in the anticoagulant reversal drugs market, the study includes a detailed section on the competition landscape of the anticoagulant reversal drugs market. The study provides a dashboard view of the report, with a detailed comparison of players operating in the anticoagulant reversal drugs market, based on total revenue, market presence, and key developments. In addition to this, key strategies and recent developments implemented by players in the anticoagulant reversal drugs market have also been included in this comprehensive study.

Besides magnifying focus on the crucial segments, this exclusive study also offers information on the anticoagulant reversal drugs market at a country level, to identify the underlying opportunities available for players in the anticoagulant reversal drugs market for the forecast period. Among all the estimated data, the report also includes Y-o-Y growth projections, which can help market players in comprehending the precise trajectory at which the anticoagulant reversal drugs market has been growing.

Key companies profiled in the anticoagulant reversal drugs market include Perosphere Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Portola Pharmaceuticals, Inc., CSL Limited, Octapharma AG, Amneal Pharmaceuticals Inc., Bausch Health Companies, Inc., Fresenius Kabi AG, and Pfizer, Inc.

Anticoagulant Reversal Drugs Market - Research Methodology

The anticoagulant reversal drugs market has been evaluated by taking a top-down and bottom-up approach. Demand, geographical presence, distribution strategies by manufacturers, and initiatives taken by governments and NGOs are various factors considered while estimating the revenue of the anticoagulant reversal drugs market, and thus, reaching global numbers. The study on the anticoagulant reversal drugs market is further validated through extensive primary research on the data extracted from exhaustive secondary research.

In order to conduct secondary research, annual company reports, company websites, data from the World Health Organization (WHO), SEC filings, press releases, investor presentations, and other similar resources were studied. Both, the top-down and bottom-up approaches were undertaken by analysts of the report to find accurate data regarding the growth of the anticoagulant reversal drugs market. To validate the information compiled through secondary research, interviews with key opinion leaders and subject matter experts were scheduled. The analysis aims at studying the business environment, unmet needs of consumers, key restraints, historical sales pattern, and investment landscape. In addition to this, authors of the report also had email and telephonic interactions with the senior management of leading and prominent companies to confirm the size, growth trends, and future outlook of the anticoagulant reversal drugs market.


1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Acronyms Used
3. Research Methodology
4. Executive Summary
5. Market Overview
5.1. Product Overview
5.2. Market Dynamics
5.2.1. Drivers
5.2.1.1. Rise in the prevalence of atrial fibrillation in aging population
5.2.1.2. Increase in the prevalence of ICH and GI hemorrhages
5.2.1.3. NTAP status for specific drugs
5.2.2. Restraints
5.2.2.1. Challenges associated with the development of anticoagulant reversal drugs
5.2.2.2. Risk associated with reversing anticoagulation
5.2.3. Opportunities
5.2.3.1. Unmet clinical needs
5.2.3.2. Untapped market in emerging economies
5.2.4. Global Anticoagulant Reversal Drugs Market Value (US$ Mn) Forecast, 2016?2026
5.2.5. Global Anticoagulant Reversal Drugs Market Outlook
5.2.6. Key Industry Developments
5.2.7. Regulatory Scenario
5.2.8. Reimbursement Scenario
5.2.9. Pipeline Analysis
5.2.10. Healthcare Overview
6. Global Anticoagulant Reversal Drugs Market Analysis, by Product
6.1. Introduction
6.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product
6.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016?2026
6.3.1. Prothrombin Complex Concentrates (PCC)
6.3.2. Vitamin K
6.3.3. Protamine
6.3.4. Tranexmic Acid
6.3.5. Idarucizumab
6.3.6. Andexxa
6.3.7. Others
6.4. Market Attractiveness, by Product
7. Global Anticoagulant Reversal Drugs Market Analysis, by Distribution Channel
7.1. Introduction
7.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel
7.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Others
7.4. Market Attractiveness, by Distribution Channel
8. Global Anticoagulant Reversal Drugs Market Analysis, by Region
8.1. Introduction
8.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Anticoagulant Reversal Drugs Market Analysis
9.1. Key Findings
9.2. North America Anticoagulant Reversal Drugs Market Value Forecast, by Country, 2016?2026
9.2.1. U.S.
9.2.2. Canada
9.3. North America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
9.3.1. Prothrombin Complex Concentrates (PCC)
9.3.2. Vitamin K
9.3.3. Protamine
9.3.4. Tranexmic Acid
9.3.5. Idarucizumab
9.3.6. Andexxa
9.3.7. Others
9.4. North America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Others
9.5. North America Market Attractiveness Analysis
9.5.1. By Country
9.5.2. By Product
9.5.3. By Distribution Channel
10. Europe Anticoagulant Reversal Drugs Market Analysis
10.1. Key Findings
10.2. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
10.2.1. U.K.
10.2.2. Germany
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
10.3.1. Prothrombin Complex Concentrates (PCC)
10.3.2. Vitamin K
10.3.3. Protamine
10.3.4. Tranexmic Acid
10.3.5. Idarucizumab
10.3.6. Andexxa
10.3.7. Others
10.4. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Europe Market Attractiveness Analysis
10.5.1. By Country/Sub-region
10.5.2. By Product
10.5.3. By Distribution Channel
11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis
11.1. Key Findings
11.2. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
11.2.1. China
11.2.2. Japan
11.2.3. India
11.2.4. Australia
11.2.5. Rest of Asia Pacific
11.3. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
11.3.1. Prothrombin Complex Concentrates (PCC)
11.3.2. Vitamin K
11.3.3. Protamine
11.3.4. Tranexmic Acid
11.3.5. Idarucizumab
11.3.6. Andexxa
11.3.7. Others
11.4. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Asia Pacific Market Attractiveness Analysis
11.5.1. By Country/Sub-region
11.5.2. By Product
11.5.3. By Distribution Channel
12. Latin America Anticoagulant Reversal Drugs Market Analysis
12.1. Key Findings
12.2. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
12.2.1. Brazil
12.2.2. Mexico
12.2.3. Rest of Latin America
12.3. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
12.3.1. Prothrombin Complex Concentrates (PCC)
12.3.2. Vitamin K
12.3.3. Protamine
12.3.4. Tranexmic Acid
12.3.5. Idarucizumab
12.3.6. Andexxa
12.3.7. Others
12.4. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Latin America Market Attractiveness Analysis
12.5.1. By Country/Sub-region
12.5.2. By Product
12.5.3. By Distribution Channel
13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026
13.2.1. GCC Countries
13.2.2. South Africa
13.2.3. Israel
13.2.4. Rest of Middle East & Africa
13.3. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026
13.3.1. Prothrombin Complex Concentrates (PCC)
13.3.2. Vitamin K
13.3.3. Protamine
13.3.4. Tranexmic Acid
13.3.5. Idarucizumab
13.3.6. Andexxa
13.3.7. Others
13.4. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5. Middle East & Africa Market Attractiveness Analysis
13.5.1. By Country/Sub-region
13.5.2. By Product
13.5.3. By Distribution Channel
14. Competitive Landscape
14.1. Competition Matrix
14.2. Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)
14.3. Company Profiles
14.3.1. Bausch Health Companies, Inc.
14.3.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer, Inc.
14.3.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.3. Fresenius Kabi AG
14.3.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.4. Amneal Pharmaceuticals, Inc.
14.3.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. Boehringer Ingelheim GmbH
14.3.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. CSL Limited
14.3.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.7. Octapharma AG
14.3.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.8. Portola Pharmaceuticals, Inc.
14.3.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Perosphere Pharmaceuticals, Inc. (acquired by AMAG Pharmaceuticals, Inc.)
14.3.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
List of Tables
Table 01: Reimbursement Scenario for AndeXXa
Table 02: Reimbursement Scenario for Praxbind
Table 03: Reimbursement Scenario for Kcentra
Table 04: Pipeline Analysis
Table 05: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 06: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 07: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Region, 2016–2026
Table 08: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country, 2016–2026
Table 09: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 10: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 11: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 12: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 13: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 14: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 15: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 16: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 17: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 19: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 20: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2016–2026
Table 22: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2016–2026
List of Figures
Figure 01: Anticoagulant Reversal Drugs Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02: Global Anticoagulant Reversal Drugs Market Size (US$ Mn) and Forecast, 2018–2026
Figure 03: Market Value Share, by Product (2018)
Figure 04: Market Value Share, by Distribution Channel (2018)
Figure 05: Market Value Share, by Region (2018)
Figure 06: Regulatory Approval Process - U.S.
Figure 07: Regulatory Approval Process - Europe
Figure 08: Regulatory Approval Process - Japan
Figure 09: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 10: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Prothrombin Complex Concentrates (PCC) 2016–2026
Figure 11: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Vitamin K, 2016–2026
Figure 12: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Protamine, 2016–2026
Figure 13: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Tranexamic Acid, 2016–2026
Figure 14: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2016–2026
Figure 15: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Idarucizumab, 2016–2026
Figure 16: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by AndeXXa, 2016–2026
Figure 17: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 18: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 19: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 20: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 21: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 22: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2016–2026
Figure 23: Global Anticoagulant Reversal Drugs Market Value Share, by Region, 2017 and 2026
Figure 24: Global Anticoagulant Reversal Drugs Market Attractiveness, by Region, 2018–2026
Figure 25: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 26: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country, 2017 and 2026
Figure 27: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country, 2018-2026
Figure 28: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 29: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 30: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 31: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 32: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 33: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 34: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018-2026
Figure 35: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 36: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 37: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 38: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 39: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 40: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 41: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 42: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 43: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 44: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 45: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 46: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 47: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 48: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 49: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 50: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 51: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 52: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 53: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 54: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 55: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 56: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2017 and 2026
Figure 57: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2018–2026
Figure 58: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 59: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 60: Global Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)
Figure 61: Product Overview - Bausch Health Companies, Inc.
Figure 62: Breakdown of Net Sales (%), by Region, 2017 - Bausch Health Companies, Inc.
Figure 63: Revenue (US$ Mn), 2015–2017 - Bausch Health Companies, Inc.
Figure 64: R&D Expenses (US$ Mn), 2015-2017 - Bausch Health Companies, Inc.
Figure 65: Product Overview - Pfizer, Inc.
Figure 66: Breakdown of Net Sales, by Region, 2017 - Pfizer, Inc.
Figure 67: Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017 - Pfizer, Inc.
Figure 68: R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017 - Pfizer, Inc.
Figure 69: Product Overview - Fresenius Kabi AG
Figure 70: Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017 - Fresenius Kabi AG
Figure 71: Breakdown of Net Sales, by Region, 2017 - Fresenius Kabi AG
Figure 72: Breakdown of Net Sales, by Segment, 2017 - Fresenius Kabi AG
Figure 73: Research & Development Cost, 2016 - 2017 (US$ Mn) - Fresenius Kabi AG
Figure 74: Product Overview - Amneal Pharmaceuticals, Inc.
Figure 75: Product Overview - Boehringer Ingelheim GmbH
Figure 76: Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017 - Boehringer Ingelheim GmbH
Figure 77: Breakdown of Net Sales, by Business and Business Segment Level, 2017 - Boehringer Ingelheim GmbH
Figure 78: Breakdown of Net Sales, by Region (Company Level), 2017 - Boehringer Ingelheim GmbH
Figure 79: R&D Expenditure (US$ Bn), 2013–2017 - Boehringer Ingelheim GmbH
Figure 80: Product Overview: CSL Limited
Figure 81: Total Revenue (US$ Mn) and Y-o-Y Growth, 2016–2018 – CSL Limited
Figure 82: R&D Investment, (US$ Mn) and Y-o-Y Growth, 2016–2018 - CSL Limited
Figure 83: Sales Revenue (US$ Mn) and Y-o-Y Growth, 2016–2018 - CSL Limited
Figure 84: Net Profit (US$ Mn), 2016–2018 - CSL Limited
Figure 85: Product Overview - Octapharma AG
Figure 86: Revenue (US$ Mn) and Y-o-Y Growth, 2015–2017 - Octapharma AG
Figure 87: R&D and Selling and Marketing Expenses, (US$ Mn), 2016–2017 - Octapharma AG
Figure 88: Year-end Employee Headcount and Y-o-Y Growth, 2015-2017 - Octapharma AG
Figure 89: Gross profit (US$ Mn) and Y-o-Y Growth, 2016–2017 - Octapharma AG
Figure 90: Product Overview - Portola Pharmaceuticals, Inc.
Figure 91: R&D and Selling and Marketing Expenses, (US$ Mn), 2016–2017 - Portola Pharmaceuticals, Inc.
Figure 92: Revenue (US$ Mn) and Y-o-Y Growth, 2015–2017 - Portola Pharmaceuticals, Inc.
Figure 93: Product Overview - Perosphere Pharmaceuticals Inc.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook